[Augmented indication field for Convulex therapy (author's transl)].

The therapeutic effect of n-dipropylacetate (DPA) is described in 20 patients with cerebral or spinal spasticity. Improvement was ween in 8 out of 11 patients with cerebral spasticity, 3 out of 5 patients with spinal spasticity and 3 out of 4 cases who had sustained perinatal damage. Satisfactory clinical amelioration and improvement in the EEG was observed in myoclonia, particularly of the Unverricht-Lundborg type.